This protocol provided a template for future multiple centers, chambered chamber-bags. The protocol is consigned balance and efficacy, uh, clinical maneuverability so as to provide practical model for future research. This method could used as a reference for studies of parentaly administered and medical nutrition, especially for triple chamber-bags.
The oddity is difficult to design and implement. Reference to a similar protocol maybe a shortcut for somebody who entered this field for the first time. Part of design implementation of this study can be clearly presented by text.
To ensure a correct dosage for each of the treatments and keep the consistency of prescriptions, give each research site a table containing the exact PM composition of different weights. Administer the treatments to each participant through a peripheral intravenous catheter via a control pump. If an infusion is not possible or inadvisable via peripheral IV, infuse the study treatment via a peripherally inserted central catheter, or a central IV line.
Gradually increase the flow rate during the first hour to 50 to 100 milliliters per hour and deliver the treatment for 12 to 22 hours for at least 5, and up to 14, days. On days 1 through 5, administer only the study treatment. To assess the primary efficacy outcome measure, of the serum pre-albumin level, on day 5, obtain 2 to 3 milliliter peripheral venous blood samples from a contralateral appendage from the peripheral IV study participant as well as at the time points indicated in the assessment schedule.
Store the blood at 4 degrees celsius for up to 4 hours before transferring the samples to the central laboratory for analysis of the efficacy parameters. To assess the primary efficacy outcome measure of the urine output, collect urine for a 6 hour period on day 5, and according to the assessment schedule. Record the collected volume for the applicable treatment day before storing the sample at 4 degrees celsius.
Then transfer an aliquot from the urine collection to the central laboratory for analysis of the efficacy parameters. For safety assessment of the treatment, survey the participant about any adverse or serious adverse events, and perform a vital sign assessment and physical examination. Then perform any other laboratory assessments according to the schedule.
On day 6, and until the end of the study period, initiate the addition of liquid oral nutrition to the study treatment to meet the calculated daily nutrition requirements. Stop the study treatment once the subject receives at least 80 percent of the calculated daily nutrition requirements by the administered liquid oral nutrition or at the completion of the day 14 study treatment;whichever comes first. Upon completion or termination of the treatment, perform the appropriate end-of-treatment procedures for the participant according to the schedule.
In this representative study, a total of 62 percent of patients underwent a high complexity surgery with a mean duration of 3 hours. A similar trend was also observed when the subgroup analysis for age"gender"no surgery"surgery of medium complexity"and surgery of high complexity"was performed for the 2 groups. The overall rate of infections was found to be low in the study, with the patients in the control group demonstrating a significantly higher infection rate compared to the test group.
The most common infections observed in the study were lung infections, followed by incision and wound infections. The preparation time for the study treatment was also found to be significantly lower for the test group compared to the control group on all assessment days. First we should consider the clinical safety and the feasibility before study design.
Another point, is that minimizes the difference around different sides is important that building protocol design for emerging center study.
